This symposium will comprehensively cover the latest clinical and experimental breakthroughs in the percutaneous treatment of coronary artery disease. Those attending will be exposed to the latest clinical trial data on current and second generation drug-eluting stent device-based therapies. Controversies, including resistance and selection, of antiplatelet therapy as adjunctive treatment with percutaneous intervention will be discussed along with the use of imaging tools and how to manage complex lesions. Utilizing both didactic and case-based presentations, attendees will be exposed to the latest clinical and evidence-based medicine options to optimize patient outcomes in the treatment of coronary artery disease.

Course Directors

Martin B. Leon, MD

Gregg W. Stone, MD

Invited Faculty

New DES Directions

Bioabsorbable Polymers and Polymer-Free Stents: Theoretical Advantages and Provocative Early Results
First vs. Second Generation DES: Are There Meaningful Differences?
First Presentation of the SPIRIT IV Cost-Effectiveness Study

Adjunctive Pharmacology

Clopidogrel Resistance and Genetic Polymorphisms
Current Selection of Thienopyridines in ACS
Heparin or Bivalirudin for PCI in Stable CAD, NSTEMI, and STEMI

Adjunctive Imaging & Physiology

FFR Beyond Fame: Tips and Tricks For Optimal Use
OCT: What Are the Practical Advantages (and Disadvantages) Compared to IVUS?
Ten Cases Why You Must Use IVUS Routinely

Complex Lesion Management

AMI Intervention: The Case for DES and/or Aspiration
Borderline SVG Lesions: To Treat or Not to Treat
Left Main PCI: Selection and Strategies